Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Fixed-Dose Durvalumab Approved in Europe for Unresectable NSCLC

January 15th 2021

January 15, 2021 - Durvalumab has been approved in the European Union and the United Kingdom for a fixed-dose option of 1,500 mg every 4 weeks for use in patients with locally advanced, unresectable non–small cell lung cancer whose tumors have a PD-L1 expression of at least 1% and who have not experienced disease progression after platinum-based chemoradiation treatment.

Dr. Ramalingam on the Potential of HER2 as a Driver Mutation in NSCLC

January 14th 2021

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC

January 14th 2021

David R. Gandara, MD, discusses the benefit of nivolumab and ipilimumab in combination with chemotherapy in metastatic non–small cell lung cancer.

Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC

January 14th 2021

Howard (Jack) West, MD, discusses the use of nivolumab in combination with ipilimumab in metastatic non–small cell lung cancer.

Sintilimab Injection Second-Line Squamous NSCLC Application Accepted in China

January 14th 2021

January 14, 2020 — The National Medical Products Administration of China has accepted a supplemental new drug application for sintilimab injection for use in the second-line treatment of patients with squamous non–small cell lung cancer.

Frontline Tislelizumab/Chemo Approved in China for Advanced Squamous NSCLC

January 14th 2021

January 14, 2020 - The China National Medical Products Administration has approved tislelizumab for use in combination with 2 chemotherapy regimens in the frontline treatment of patients with advanced squamous non–small cell lung cancer.

TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer, But May Be Eclipsed by ADCs

January 14th 2021

Lecia V. Sequist, MD, MPH, discusses some of the advances that bore out in 2020 in HER2-mutant lung cancer and previewed anticipated developments in 2021.

Johnson Assumes Director Post of Lung Cancer Research at Sarah Cannon Research Institute

January 12th 2021

Melissa Johnson, MD, shares her goals for the first 100 days as program director of the Lung Cancer Research at Sarah Cannon Research Institute, the current state of the anti-TIGIT antibody tiragolumab, and the future of lung cancer treatment.

Expert Perspectives on Promising Data Discussed at the Immunotherapy Non–Small Cell Lung Cancer Workshop

January 11th 2021

Sarah Goldberg, MD, MPH, discusses a network meta-analysis of randomized trials of chemoimmunotherapy with in patients with advanced disease, data suggest that certain populations with high, and perhaps low, PD-L1 expression may not require combination therapy, which would minimize adverse event potential.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 8th 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC

January 8th 2021

January 8, 2021 — The combination of osimertinib plus bevacizumab failed to result in a statistically significant improvement in progression-free survival versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation.

Advances in Immunotherapy in Metastatic Non–Small Cell Lung Cancer

January 8th 2021

Non-small cell lung cancer is the most common histologic subtype of the disease, accounting for approximately 85% of cases. The recognition of targetable gene alterations and immune response has resulted in rapid changes to the therapeutic spectrum for NSCLC in recent years.

FDA Grants Fast Track Designation to Zenocutuzumab for Metastatic NRG1+ Solid Tumors

January 8th 2021

January 8, 2021 — The FDA has granted a fast track designation to zenocutuzumab for the treatment of patients with metastatic solid tumors that harbor NRG1 gene fusions and have progressed on standard-of-care treatment.

Need for Molecular Testing in Lung Cancer Is Underscored as Additional Targets Emerge

January 8th 2021

Yujie Zhao, MD, PhD, highlights molecular testing and how it's a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1, and RET.

Navigating Nuances in Early and Metastatic Lung Cancer Treatment

January 7th 2021

Brendon Stiles, MD, discusses his approach to treating patients with early-stage and metastatic lung cancer, the importance of molecular testing and screening, and remaining challenges in the space.

Chemoimmunotherapy Continues to Display Survival Benefits in Small Cell Lung Cancer

January 7th 2021

Yanyan Lou, MD, PhD, highlighted the role of atezolizumab, durvalumab, pembrolizumab, and nivolumab and how they have demonstrated improved survival in combination with etoposide and platinum in untreated extensive-stage small cell lung cancer, cementing checkpoint inhibition plus chemotherapy as a frontline standard.

Dr. Herbst on the Approval of Adjuvant Osimertinib in EGFR+ NSCLC

January 6th 2021

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Dr. Sequist on the Importance of Broad Molecular Testing in Lung Cancer

January 5th 2021

Lecia V. Sequist, MD, MPH, discusses the importance of implementing broad molecular testing in lung cancer.

FDA Grants Breakthrough Therapy Designation to Tiragolumab Plus Atezolizumab for PD-L1–High NSCLC

January 5th 2021

January 5th, 2021 - The FDA has granted a breakthrough therapy designation to the anti-TIGIT therapy tiragolumab for use in combination with atezolizumab in the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors are PD-L1 high and do not harbor any EGFR or ALK aberrations.

Boehringer Ingelheim Looks to Expand Targeted Therapies Portfolio

January 5th 2021

January 5, 2020 - Boehringer Ingelheim will add to its cancer cell-directed therapies portfolio with the acquisition of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 antibody-drug conjugate.